Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bydureon succeeds in FDA-mandated trial, but market uptake could prove tougher challenge

This article was originally published in Scrip

Executive Summary

Bydureon, the once-weekly antidiabetic exenatide, has overcome another obstacle to FDA approval. Developers Amylin, Eli Lilly and Alkermes have revealed that supratherapeutic doses of the compound do not cause a change in heart rhythm by affecting the QT interval.

You may also be interested in...

FDA rejection of Dapagliflozin creates uncertainty for other SGLT-2 inhibitors

Dapagliflozin, the most advanced candidate in the novel SGLT-2 inhibitor antidiabetic class, was the subject of a complete response letter from the FDA, co-developers Bristol-Myers Squibb and AstraZeneca announced on 19 January 2012. The letter was not unexpected, given a negative 9-6 vote from an FDA Advisory Committee in July 2011 which revealed concerns about possible increased risks of breast and bladder cancers seen in the aggregated Phase II and Phase III trial data, as well as a case of probable drug-induced liver injury (, 21 July 2011).

Sanofi, Pfizer, Takeda, or Roche fit partner profile for Amylin's exenatide

The decision by Amylin and Lilly to end their co-development and marketing deal covering exenatide antidiabetic products potentially opens the door to other partners that might be more committed to driving ex-US sales. The divorce was prompted by Lilly's recent link up with Boehringer Ingelheim for a competing product.

Tradjenta delay could set trend as comparator argument evolves in Germany

In September 2011 Boehringer Ingelheim and Eli Lilly announced a delay to the German launch of their novel DPP-IV inhibitor Tradjenta (linagliptin; sold in the EU as Trajenta) because of the anticipated difficulty in agreeing a suitable price with the German regulators. In Germany, most of the cost of care for most of the population is covered by a range of sickness funds funded by statutory health insurance. Furthermore, a state body - IQWiG (the Institute for Quality and Efficiency in Health Care) - is involved in setting reimbursement pricing for new medications.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts